CD163 and plasma cell myeloma: In particular, the CD163+ subpopulation of TAMs has been recognized to infiltrate the BM niche, indicating poor prognosis in myeloma [69,70,71], while elevated levels of CD163+ macrophages were also detected in other hematologic and solid cancers [72,73,74,75].